NCT04077684View on ClinicalTrials.gov

Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial

PHASE2CompletedINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

March 7, 2024

Study Completion Date

August 30, 2024

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Interleukin-2

IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT04077684 - Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial | Biotech Hunter | Biotech Hunter